Thyroseq V3 genomic classifier (GC) testing
Active Purchase Order Awarded Last action
- Contract number
- 36C25026P0252
- Awardee
-
Cytopath Biopsy Lab Inc. UEI KC5VWAGMNLT6
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $146,250
Award facts
- Opportunity
-
- Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services Special Notice · 36C25026Q0104 · Posted Nov 4, 2025
- Contract value 100% obligated
- $146,250.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Cleveland, OH 44106, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs Veterans Integrated Service Network 10 (VISN 10) awarded a $146,250 firm fixed-price purchase order to Cytopath Biopsy Lab Inc. (operating as Cblpath) for ThyroSeq V3 Genomic Classifier (GC) testing services. The contract, awarded on December 29, 2025, with an ultimate completion date of December 28, 2026, will be performed at the Cleveland, OH location. This contract continues Cblpath's established role as a specialized provider of molecular diagnostic testing services to the VA, specifically supporting thyroid cancer screening and diagnosis initiatives across the veterans healthcare system. The procurement was not set-aside and represents a continuation of the company's primary business line of providing advanced genomic sequencing and molecular diagnostic laboratory services to federal healthcare agencies.
Cblpath has demonstrated significant contracting presence with the VA across multiple regional networks, with prior contract awards ranging from $70,000 to over $2.2 million. The company specializes in providing proprietary molecular diagnostic testing that analyzes genetic mutations in thyroid nodules to assess cancer risk and support clinical decision-making for veteran patients. This award is consistent with Cblpath's established service delivery model to VISN networks and reflects the company's competitive positioning as a primary federal contractor for specialized genomic testing services supporting cancer screening programs within the Department of Veterans Affairs healthcare network.
Quick answers
Who was awarded contract 36C25026P0252?
36C25026P0252 was awarded to Cytopath Biopsy Lab Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on December 29, 2025.
How much is contract 36C25026P0252 worth?
The government has obligated $146,250 on 36C25026P0252.
Was contract 36C25026P0252 competed?
The extent of competition for 36C25026P0252 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award